GUIDELINES

The PanCare Guidelines Group aims to promote and facilitate the development of guidelines for the care of childhood and adolescent cancer survivors across Europe, and to support the implementation of recommendations in these guidelines. Guidelines make it easier for health care professional and survivors to plan the best possible long-term follow-up care for each person.

The PanCare Guidelines Group

helps PanCare members to be aware of survivor care guidelines that are being developed by PanCare or by other guideline groups and projects
supports guideline development by identifying European experts to join survivor care guideline panels
will identify which guidelines need to be updated
oversees and supports the implementation of guidelines into major European survivor care projects
supports and participates in the development of easily understandable lay information about survivor care guidelines

PanCare follow-up recommendations for surveillance of late effects

The recommendations for surveillance of late effect were developed within PanCareFollowUp.

Click here to view the PanCare follow-up recommendations for surveillance of late effects

IGHG guidelines

The IGHG guidelines below can be found on the website of the IGHG. These IGHG guidelines include recommendations for surveillance of chronic health problems (late effects) in survivors of childhood, adolescent and young adult cancer. By clicking on a specific guideline you will be redirected to the guideline at the IGHG website.

Breast cancer surveillance
- Recommendations for surveillance for breast cancer in female survivors who were treated with radiotherapy exposing breast tissue.
Cardiomyopathy surveillance
- Recommendations for surveillance for cardiomyopathy in survivors who were treated with anthracycline chemotherapy or chest radiotherapy or both.
Premature ovarian insufficiency surveillance
- Recommendations for surveillance in female survivors who were treated with chemotherapy or radiotherapy that may increase their risk of premature ovarian insufficiency.
Male gonadotoxicity surveillance
- Recommendations for surveillance in male survivors who were treated with chemotherapy, radiotherapy or surgery that may increase their risk of impaired spermatogenesis, testosterone deficiency or physical sexual dysfunction.
Thyroid cancer surveillance
- Recommendations for surveillance for thyroid cancer in survivors who were treated with radiotherapy exposing the thyroid gland.
Ototoxicity surveillance
- Recommendations for surveillance for ototoxicity (hearing loss, tinnitus, or both) in survivors who were treated with platinum chemotherapy or radiotherapy to the brain or ear.
Fatigue surveillance
- Recommendations for surveillance for cancer-related fatigue in survivors.
Central nervous system neoplasms surveillance
- Recommendations for surveillance for central nervous system neoplasms in survivors who were treated with cranial radiotherapy.
Obstetric care
- Recommendations for obstetric care in female survivors.
Fertility preservation
- Recommendations for fertility preservation in patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment.
Bone mineral density surveillance
- Recommendations for surveillance for reduced bone mineral density in survivors
Coronary artery disease surveillance
- Recommendations for surveillance for coronary artery disease in survivors
Hepatic toxicity surveillance
- Recommendations for surveillance for hepatic toxicity in survivors
Mental health problems surveillance
- Recommendations for surveillance for mental health problems in survivors
Education and employment outcomes surveillance
- Recommendations for surveillance for education and employment outcomes in survivors
Hypothalamic-pituitary dysfunction surveillance
- Recommendations for surveillance for hypothalamic-pituitary dysfunction in survivors
Dexrazoxane cardioprotection

Recommendations for dexrazoxane administration in children with cancer expected to receive anthracyclines.

Pulmonary dysfunction surveillance

Recommendations for the surveillance of pulmonary dysfunction insurvivors

COVID-19 statement

Guidance to childhood, adolescent and young adult cancer survivors related to risk and additional preventive measures for COVID-19

The International Late Effects of Childhood Cancer Guideline Harmonization Group, IGHG, is a worldwide endeavor initiated by several national guideline groups and the Cochrane Childhood Cancer Group in partnership with the PanCare Guidelines Group to collaborate in guideline development.

The main goal of the IGHG is to establish a common vision and integrated strategy for the surveillance of chronic health problems and subsequent cancers in childhood, adolescent, and young adult cancer survivors.

By international collaboration in guideline development the IGHG aims to reduce duplication of effort, optimize the quality of care, and improve quality of life for childhood, adolescent, and young adult cancer survivors.

The Following guidelines were developed within the PanCareSurFup project.
These PanCareSurFup guidelines include recommendations for the delivery of long-term follow-up care in survivors of childhood and adolescent cancer.

Mulder RL, van der Pal HJH, Levitt G, Skinner R, Kremer LCM, Brown MC, Bárdi E, Windsor R, Michel G, Frey E. Transition guidelines: An important step in the future care for childhood cancer survivors. A comprehensive definition as groundwork. Eur J Cancer 2016; 54: 64-68.
- Evidence-based definition of the concept of transition of care for survivors of childhood cancer

Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, Vetsch J, Frey E, Windsor R, Kremer LCM, Levitt G. Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019; 13: 759-772.
- Recommendations for the organisation of long-term follow-up care of childhood and adolescent cancer survivors